Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
84 participants
OBSERVATIONAL
2024-10-31
2025-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To compare between Asprosin and the routine markers (CEA, CA15-3) as biomarkers for breast cancer diagnosis
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Serum IL-7 as a Biomarker in Breast Cancer
NCT07133685
Nipple Aspirate Fluid in Detecting Breast Cancer
NCT03715959
Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer
NCT00897416
Prognostic Significance of Bioscore in Nonmetastatic Breast Cancer
NCT03638219
Retrospective Comparative in Vitro Case-controlled Study of the Liquid Biopsy Test System in Women With Breast Cancer
NCT04927130
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy people
ELISA
Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).
Patients with benign breast lesions
ELISA
Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).
Patients with breast cancer
ELISA
Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ELISA
Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Females aged (40 ± 20 years) who did not receive any chemotherapy or surgical treatment and they will be divided as follow:
Group 1: healthy controls from healthy volunteers. Group 2: patients with benign breast lesions. Group 3: breast cancer patients.
Exclusion Criteria
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Marina Hanna Thabet Ghobrial
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marina Hanna Thabet Ghobrial
Assistant Lecturer
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Eman Mohamed Abdelrahman
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Asprosin
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.